Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC9733-0001 in Healthy Participants and Participants With Type 2 Diabetes
NCT07270731Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Nov 2025
- Primary completion
- Mar 2028
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised trial in type 2 diabetes mellitus (T2DM) comparing NNC9733-0001 with Placebo (2 arms). Primary endpoints: Treatment Emergent Adverse Events at 36 weeks and Hypoglycaemic episodes at 36 weeks. Started Nov 2025; status: recruiting.
02
Drugs
NNC9733-0001
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07270731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07270731.